IGC Pharma, Inc.
IGCAMEXHealthcare● Active
$0.29
$-0.01(-2.14%)
Market Cap$29286627
P/E Ratio—
52W High$0.5
52W Low$0.24
IGC Pharma, Inc. (IGC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IGC · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 3, 2026EPS Actual
-$0.02
Est. -$0.02 · +0.0%
Revenue
$0.00B
Est. $0.00B · -1.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 3, 2026
After Market Close
▼ Miss Revenue🔥 6-Quarter EPS Beat Streak
IGC reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Nov 18, 2026 | -$0.02 | — | — | — | $0.00B | — |
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.02 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | Jun 26, 2026 | -$0.02 | — | — | — | $0.00B | — |
| — Q2 FY2026 | Apr 3, 2026 | -$0.02 | -$0.02 | +0.0% | $0.00B | $0.00B | -1.4% |
| — Q4 FY2025 | Nov 14, 2025 | -$0.02 | -$0.02 | +0.0% | $0.00B | $0.00B | -50.1% |
| ▲ Q3 FY2025 | Aug 19, 2025 | -$0.03 | -$0.02 | +20.0% | $0.00B | $0.00B | +0.6% |
| — Q2 FY2025 | Jun 30, 2025 | -$0.02 | -$0.02 | +0.0% | $0.00B | $0.00B | -14.8% |
| ▲ Q1 FY2025 | Feb 18, 2025 | -$0.03 | -$0.02 | +33.3% | $0.00B | $0.00B | +26.0% |
Q4 FY2026
Nov 18, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 26, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 3, 2026
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Aug 19, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.03
EPS Surpr.
+20.0%
Revenue
$0.00B
Q2 FY2025
Jun 30, 2025
EPS Actual
-$0.02
EPS Est.
-$0.02
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
-$0.02
EPS Est.
-$0.03
EPS Surpr.
+33.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q1 FY2027 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q4 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 3, 2026 | +0.0% | $0.27 | $0.27 | +1.13% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +0.0% | $0.36 | $0.36 | +0.56% |
| ▲ Q3 FY2025 | Aug 19, 2025 | +20.0% | $0.38 | $0.37 | -2.26% |
| ▲ Q2 FY2025 | Jun 30, 2025 | +0.0% | $0.31 | $0.31 | -0.97% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +33.3% | $0.31 | $0.31 | -2.09% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +33.3% | $0.37 | $0.36 | -2.59% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -15.9% | $0.39 | $0.39 | +1.30% |
| ▼ Q2 FY2024 | Jun 24, 2024 | -900.0% | $0.55 | $0.47 | -14.65% |
Q2 FY2026+1.13%
Report Date
Apr 3, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.27
Price After
$0.27
Q4 FY2025+0.56%
Report Date
Nov 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.36
Price After
$0.36
Q3 FY2025-2.26%
Report Date
Aug 19, 2025
EPS Beat/Miss
+20.0%
Price Before
$0.38
Price After
$0.37
Q2 FY2025-0.97%
Report Date
Jun 30, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.31
Price After
$0.31
Q1 FY2025-2.09%
Report Date
Feb 18, 2025
EPS Beat/Miss
+33.3%
Price Before
$0.31
Price After
$0.31
Q4 FY2024-2.59%
Report Date
Nov 14, 2024
EPS Beat/Miss
+33.3%
Price Before
$0.37
Price After
$0.36
Q3 FY2024+1.30%
Report Date
Aug 8, 2024
EPS Beat/Miss
-15.9%
Price Before
$0.39
Price After
$0.39
Q2 FY2024-14.65%
Report Date
Jun 24, 2024
EPS Beat/Miss
-900.0%
Price Before
$0.55
Price After
$0.47
Avg Beat Reaction-1.04%
Avg Miss Reaction-6.67%
Beat Rate6 / 8 quarters
Largest Move-14.65% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IGC ends December
IGC Pharma, Inc. (IGC) most recently reported earnings on April 3, 2026 for Q2 FY2026, posting EPS of $-0.02 (in line with the analyst consensus of $-0.02). IGC has beaten EPS estimates for 6 consecutive quarters. The next IGC earnings date is expected around September 1, 2026.
Each quarter, investors track IGC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IGC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IGC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IGC earnings · 4 questionsIGC Pharma, Inc.'s next earnings report is expected around September 1, 2026. IGC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IGC historically reports after market close (AMC).
IGC earnings datewhen is IGC earningsIGC next earnings datewhen does IGC report earningsIGC earnings calendar
▸ Source: FMP · IGC Pharma, Inc. SEC filings · US GAAP · IGC Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026